Summary
- Current Price
- As of today, JAZZ price is $244.96, down -0.36% on
- Current Price All-Time High
- JAZZ price is currently -7.58% below its historical high of $265.05 set on
- Market Cap
- JAZZ current market cap is $16B, up +124.76% over the past 365 days
- PE Ratio
- JAZZ current PE ratio is 16.89
- Revenue
- JAZZ current annual revenue is $4.27B, up +4.88% year-over-year
- Next Earnings
- The next earnings release for JAZZ is on
Profile
| Metric | Value |
|---|---|
| Full Name | Jazz Pharmaceuticals plc |
| Ticker | NASDAQ: JAZZ |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Ireland |
| IPO | |
| Indexes | Not included |
| Website | jazzpharma.com |
| Employees | 2,800 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $244.96 | |
| Price, 1D Change | -0.36% | |
| Market Cap | $16B | |
| - | ||
| PE Ratio | 16.89 | |
| Beta | 0.47 | |
| Revenue | $4.27B | |
| Revenue, 1Y Change | +4.88% | |
| EPS | -$5.84 | |
| EPS, 1Y Change | -167.53% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | -$5.84 | |
| EPS Estimate | $25.03 | N/A |
| EPS Est. Change | +528.61% | N/A |
| Revenue | $4.27B | |
| Revenue Estimate | $4.71B | N/A |
| Revenue Est. Change | +10.31% | N/A |
| Current Price | $244.96 | |
| Price Target | $285.00 | - |
| Price Tgt. Change | +16.35% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $20.21 | $8.65 | -57.21% | |
| $8.19 | -$5.84 | -171.28% | |
| $25.03 | N/A | +528.61% | |
| $25.77 | N/A | +541.23% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $4.04B | $4.07B | +0.70% | |
| $4.24B | $4.27B | +0.68% | |
| $4.71B | N/A | +10.31% | |
| $4.97B | N/A | +16.54% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +109.96% | |
| Price, 3Y | +74.97% | |
| Market Cap, 1Y | +124.76% | |
| Market Cap, 3Y | +79.16% | |
| Revenue, 1Y | +4.88% | |
| Revenue, 3Y | +16.62% | |
| EPS, 1Y | -167.53% | |
| EPS, 3Y | -63.01% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $244.96 | |
| SMA 200 | $197.19 | |
| SMA 50 | $243.02 | |
| EMA 200 | $203.09 | |
| EMA 50 | $243.06 | |
| MACD | $1.60 | |
| Beta | 0.47 | |
| ATR | $7.25 | |
| 14-Day RSI | 44.46 | |
| 10-Day Volatility | 29.81% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $4.27B | |
| EPS | -$5.84 | |
| Gross Profit | $3.11B | |
| Gross Margin | 72.87% | |
| Operating Income | $751.12M | |
| Operating Margin | 17.60% | |
| Net Income | -$356.15M | |
| Net Margin | -8.35% | |
| EBITDA | $1.45B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 1.26 | |
| 1.86 | ||
| 1.67 | ||
| - | ||
| 8 | ||
| 2.15 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | 16.89 | |
| 3.46 | ||
| 3.31 | ||
| 10.83 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $4.32B | |
| $2.44B | ||
| $11.66B | ||
| $4.17B | ||
| $7.34B | ||
| $2.24B | ||
| Total Debt | $5.43B | |
| $1.04B | ||
| $122.06M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $4.62B | ||
| $2.36B | ||
| $1.16B | ||
| $0.00 | ||
| $696.30M | ||
| $0.00 | ||
| -$272.44M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $1.36B | ||
| -$1.51B | ||
| -$873.38M | ||
| Capex | $167.25M | |
| $1.19B |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Morgan Stanley | → | |
| Wells Fargo | → | |
| Truist Securities | → | |
| TD Cowen | → | |
| Piper Sandler | → | |
| Needham | → | |
| Morgan Stanley | → | |
| JP Morgan | → | |
| Barclays | → | |
| Baird | → |
Analyst sentiment
Institutional ownership
Screeners with JAZZ
FAQ
- What is the ticker symbol for Jazz Pharmaceuticals plc?
- The ticker symbol for Jazz Pharmaceuticals plc is NASDAQ:JAZZ
- Does Jazz Pharmaceuticals plc pay dividends?
- No, Jazz Pharmaceuticals plc does not pay dividends
- What sector is Jazz Pharmaceuticals plc in?
- Jazz Pharmaceuticals plc is in the Healthcare sector
- What industry is Jazz Pharmaceuticals plc in?
- Jazz Pharmaceuticals plc is in the Biotechnology industry
- What country is Jazz Pharmaceuticals plc based in?
- Jazz Pharmaceuticals plc is headquartered in Ireland
- When did Jazz Pharmaceuticals plc go public?
- Jazz Pharmaceuticals plc initial public offering (IPO) was on June 1, 2007
- Is Jazz Pharmaceuticals plc in the S&P 500?
- No, Jazz Pharmaceuticals plc is not included in the S&P 500 index
- Is Jazz Pharmaceuticals plc in the NASDAQ 100?
- No, Jazz Pharmaceuticals plc is not included in the NASDAQ 100 index
- Is Jazz Pharmaceuticals plc in the Dow Jones?
- No, Jazz Pharmaceuticals plc is not included in the Dow Jones index
- When was Jazz Pharmaceuticals plc last earnings report?
- Jazz Pharmaceuticals plc's most recent earnings report was on August 3, 2026
- When does Jazz Pharmaceuticals plc report earnings?
- The next expected earnings date for Jazz Pharmaceuticals plc is November 4, 2026
Data Sources & References
- JAZZ Official Website www.jazzpharma.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1232524/000123252426000013/0001232524-26-000013-index.htm
- JAZZ Profile on Yahoo Finance finance.yahoo.com/quote/JAZZ
- JAZZ Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/jazz